Neuralstem Inc. has received the green light to begin the first human stem cell trial to treat Amyotrophic Lateral Sclerosis (ALS), often referred to as Lou Gehrig’s disease. The company’s stock soared on the news.
Neuralstem has only received approval for the first stage of the trial that would consist of 12 patients who will receive stem cell injections in the lumbar area of the spinal cord.
Neuralstem said the trial will be under the direction of principal investigator Dr. Eva L. Feldman, Director of the University of Michigan Health System ALS Clinic and the Program for Neurology Research & Discovery.
Emory University researchers are participating in a groundbreaking clinical trial to treat patients with amyotrophic lateral sclerosis (ALS) using human neural stem cells.
The Phase 1 trial, will assess the safety of stem cells, and the surgical procedures and devices required, for multiple injections of the cells directly into the spinal cord.
“This is the first U.S. clinical trial of stem cell injections into the spinal cord for the treatment of ALS,” says principal researcher Jonathan Glass, professor of neurology in the School of Medicin, and director of the Emory ALS Center. “Our main goal in this early phase is to
Image via Wikipedia
Scientists have discovered a new way to generate human motor nerve cells in a development that will help research into motor neurone disease.
A team from the Universities of Edinburgh, Cambridge and Cardiff has created a range of motor neurons – nerves cells that send messages from the brain and spine to other parts of the body – from human embryonic stem cells in the laboratory.
It is the first time that researchers have been able to generate a variety of human motor neurons, which differ in their make-up and display properties depending on where they are located
Japanese stem cell scientists have succeeded in slowing the deterioration of mice with motor neuron disease, possibly paving the way for human treatment, according to a new paper.
A team of researchers from the Kyoto University and Keio University transplanted specially created cells into mice with amyotrophic lateral sclerosis (ALS), also called Lou Gehrig’s, or motor neuron disease.
The progress of the creatures’ neurological degeneration was slowed by almost 8%, according to the paper, which was published on Friday in the journal Stem Cell Reports.
Advancements in stem cell research may one day help surgeons provide treatment for Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease, a deadly neurodegenerative disease characterized by the selective death of motor neurons.
CD133+ stem cells are known to have the capacity to differentiate into neural lineages and may provide an alternative treatment for patients suffering from ALS and other neurodegenerative diseases.
According to Newswise, Linda Kelley, Ph.D., director of the University of Utah’s Cell Therapy Facility, James Campanelli, Ph.D., of University of Utah spin-out Q Therapeutics, Inc., and Utah native Nicholas Maragakis, M.D., of The Johns Hopkins University